

CONTENTS

Acknowledgments	4
Preface	6
<hr/>	
Chapter 1: General aspects	
Medical biotechnology and sustainable drug development	7
<hr/>	
Chapter 2: What makes protein drugs different	
Some considerations on shifting paradigms in pharmacy...	8
Pharmaceutical aspects	11
PK/PD relationships	14
Manufacturing challenges for biosimilars: the process defines the product	16
Biopharmaceuticals and biosimilars, unravelling the complexity	19
Enzyme therapy for Pompe's disease and other lysosomal storage disorders	20
<hr/>	
Chapter 3: Clinical aspects	
Protein therapeutics and their immunogenicity	27
Clinical aspects of protein drugs	30
<hr/>	
Chapter 4: Biosimilars	
Biologicals in the era of biosimilars: implications for naming and prescribing	33
Biologicals, biosimilars, drug substitution: a mandatory sequence?	36
Legal and regulatory issues in licensing biosimilars	39
Challenges for the adoption of future biosimilars	42
<hr/>	
Chapter 5: Practical aspects and how to choose	
The supply chain for biopharmaceuticals: maintaining the correct temperature	45
Points to consider in the evaluation of biopharmaceuticals	48
Case study: the first biosimilar epoietins compared	57
<hr/>	
Chapter 6: Risk management	
Counterfeit protein drugs: how to discover and how to prevent?	60
Emerging technologies in the detection of protein falsification	63
Risk management of biopharmaceuticals: a regulatory perspective	67
A comprehensive risk management plan when administering natalizumab	70